Revolution Medicines shares rise after Q3 beats; company maintains 2026 guidance

Summary

According to Seeking Alpha headlines, Revolution Medicines shares rose after the company reported third-quarter results that beat expectations, and it maintained its 2026 guidance. A second Seeking Alpha headline says the company reiterated its 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion following the launch of RASONQUE. The available article text is limited to headlines, so no further financial figures are included.

Timeline

1. Seeking Alpha

   4 Nov 2026, 23:19 UTCSource ↗

   Reports that Revolution Medicines rose after beating third-quarter results and maintaining its 2026 guidance.

2. Seeking Alpha

   5 Nov 2026, 01:35 UTCSource ↗

   Reports that Revolution Medicines reiterated its $2.1B-$2.2B 2026 GAAP operating expense guidance following the RASONQUE launch.